Upcoming IPO: Medical gadgets firm Sahajanand Medical Applied sciences has filed its draft crimson herring prospectus (DRHP) with the capital markets regulator, the Securities and Alternate Board of India (Sebi), on Friday, July 25, 2025.
Based by Dhirajlal Kotadia in 2001, Sahajanand Medical Applied sciences (SMT) Restricted specialises in superior medical gadgets in vascular and structural coronary heart intervention. Ashish Kacholia, Samara Capital Markets Holding Restricted, Kotak Pre-IPO Alternatives Fund and Plutus Wealth Administration LLP are the foremost shareholders within the firm.
Sahajanand Medical Applied sciences IPO particulars
In line with the DRHP submitting, the corporate is providing a book-built preliminary public providing (IPO) with a completely provide on the market (OFS) part.
The corporate proposed to make an offer-for-sale of as much as 2,76,44,231 fairness shares to shareholders with a face worth of Re 1 apiece. The provide additionally supplies a reduced subscription reservation for eligible staff inside the worker reservation part.
The general public subject consists of stakes of as much as 27,00,000 fairness shares every of Shree Hari Belief and Dhirajkumar Savjibhai Vasoya, round 1,29,58,126 fairness shares by Samara Capital Markets Holding Restricted, as much as 26,15,750 fairness shares by Kotak Pre-IPO Alternatives Fund, and as much as 66,70,355 fairness shares by NHPEA Sparkle Holding B.V.
The provide is carried out by means of a book-building course of, with as much as 50% allotted to certified institutional consumers and not less than 15% and 35% assigned to non-institutional and retail particular person bidders, respectively, in response to the draft papers.
The fairness shares are proposed to be listed on the NSE and BSE. The book-running lead managers for the general public subject are Motilal Oswal Funding Advisors, Avendus Capital Personal, HSBC Securities and Capital Markets (India), and Nuvama Wealth Administration. MUFG Intime India is the registrar.
Disclaimer: This story is for instructional functions solely. The views and proposals above are these of particular person analysts or broking firms, not Mint. We advise traders to verify with licensed specialists earlier than making any funding choices, as market circumstances can change quickly, and circumstances could fluctuate.
